CoChat

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

Open access
Mattsson, Niklas, Insel, Philip S., Landau, Susan, Jagust, William, Donohue, Michael, Shaw, Leslie M., Trojanowski, John Q., Zetterberg, Henrik, Blennow, Kaj, Weiner, Michael, the Alzheimer's Disease Neuroimaging Initiative · 2014 · Annals of Clinical and Translational Neurology
Cited by 107

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Background: Reduced cerebrospinal fluid (CSF) β‐amyloid42 (A β 42) and increased florbetapir positron emission tomography (PET) uptake reflects brain A β accumulation. These biomarkers are correlated with each other and altered in Alzheimer's disease (AD), but no study has directly compared their diagnostic performance. Methods: We examined healthy controls (CN, N = 169) versus AD dementia patients (N = 118), and stable (sMCI; no dementia, followed up for at least 2 years, N = 165) versus progressive MCI (pMCI; conversion to AD dementia, N = 59). All subjects had florbetapir PET (global and regional; temporal, frontal, parietal, and cingulate) and CSF A β 42 measurements at baseline. We compared area under the curve (AUC), sensitivity, and specificity (testing a priori and optimized cutoffs). Clinical diagnosis was the reference standard. Results: CSF A β 42 and (global or regional) PET florbetapir did not differ in AUC (CN vs. AD, CSF 84.4%; global PET 86.9%; difference [95% confidence interval] −6.7 to 1.5). CSF A β 42 and global PET florbetapir did not differ in sensitivity, but PET had greater specificity than CSF in most comparisons. Sixteen CN progressed to MCI and AD (six A β negative, seven A β positive, and three PET positive but CSF negative). Interpretation: The overall diagnostic accuracies of CSF A β 42 and PET florbetapir were similar, but PET had greater specificity. This was because some CN and sMCI subjects appear pathological using CSF but not using PET, suggesting that low CSF A β 42 not always translates to cognitive decline or brain A β accumulation. Other factors, including costs and side effects, may also be considered when determining the optimal modality for different applications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/acn3.81

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 107

Metadata

Authors
Mattsson, N., Insel, P. S., Landau, S., Jagust, W., Donohue, M., Shaw, L. M., Trojanowski, J. Q., Zetterberg, H., Blennow, K., Weiner, M., & Initiative, T. A. D. N.
Venue
Annals of Clinical and Translational Neurology
Publisher
Wiley
Published
2014-07-19
Volume
1
Issue
8
Pages
534-543
ISSN
2328-9503 (ISSN-L)
OpenAlex
W1964472291
Cited by
107
References
24
FWCI
9.21
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. https://app.cochat.ai/papers/10.1002/acn3.81
The paper
Mattsson, N., Insel, P. S., Landau, S., Jagust, W., Donohue, M., Shaw, L. M., Trojanowski, J. Q., Zetterberg, H., Blennow, K., Weiner, M., & Initiative, T. A. D. N. (2014). Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.81

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.